Holen Sie sich die Stockscreener-App
3.435
2.13%
-0.085
Schlusskurs vom Vortag:
$3.52
Offen:
$3.55
24-Stunden-Volumen:
2.67M
Relative Volume:
0.68
Marktkapitalisierung:
$1.04B
Einnahmen:
$75.13M
Nettoeinkommen (Verlust:
$-146.41M
KGV:
-7.0045
EPS:
-0.4904
Netto-Cashflow:
$-174.43M
1W Leistung:
+5.03%
1M Leistung:
-0.14%
6M Leistung:
-41.31%
1J Leistung:
+64.83%
1-Tages-Spanne:
$3.42
$3.585
1-Wochen-Bereich:
$3.35
$3.67
52-Wochen-Spanne:
$1.8906
$6.515
Abcellera Biologics Inc Stock (ABCL) Company Profile
Firmenname
Abcellera Biologics Inc
Sektor
Branche
Telefon
(604) 559-9005
Adresse
150 W 4TH AVENUE, VANCOUVER
Compare ABCL vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABCL
Abcellera Biologics Inc
|
3.435 | 1.07B | 75.13M | -146.41M | -174.43M | -0.4904 |
VRTX
Vertex Pharmaceuticals Inc
|
433.63 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.48 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
747.68 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.95 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.56 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-07-07 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-08-20 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2024-02-22 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-12-05 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2023-11-06 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2023-10-13 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-02-28 | Eingeleitet | Cowen | Outperform |
| 2022-12-15 | Eingeleitet | Goldman | Buy |
| 2022-11-16 | Eingeleitet | Truist | Buy |
| 2021-12-21 | Eingeleitet | The Benchmark Company | Buy |
| 2021-11-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-01-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-01-05 | Eingeleitet | Berenberg | Buy |
| 2021-01-05 | Eingeleitet | Credit Suisse | Outperform |
| 2021-01-05 | Eingeleitet | SVB Leerink | Outperform |
| 2021-01-05 | Eingeleitet | Stifel | Buy |
Alle ansehen
Abcellera Biologics Inc Aktie (ABCL) Neueste Nachrichten
Insider Stock Buying Reaches US$1.04m On AbCellera Biologics - Moomoo
AbCellera (ABCL): Among the stocks that could 10x over the next 5 years - MSN
What sparked AbCellera Biologics to soar over 9% after hours - MSN
AbCellera Biologics Inc. (ABCL) stock price, news, quote and history - Yahoo Finance UK
AbCellera Biologics Inc. (ABCL) Stock Price, News, Quote & History - Yahoo! Finance Canada
AbCellera (ABCL): Among the Stocks That Could 10x Over the Next 5 Years - Insider Monkey
AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026 - PharmiWeb.com
Press Release: AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026 - 富途牛牛
5 Stocks That Could 10X Over the Next 5 Years - Insider Monkey
Aug Gainers: Why is AbCellera Biologics Inc stock going down2026 Final Week & AI Driven Stock Reports - baoquankhu1.vn
ABCL SEC FilingsAbcellera Biologics Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Update Report: What is AbCellera Biologics Incs P E ratio telling usTrade Signal Summary & Daily Entry Point Trade Alerts - baoquankhu1.vn
Tudor Investment Corp ET AL Makes New Investment in AbCellera Biologics Inc. $ABCL - MarketBeat
AbCellera: Dart-Board Approach Reflects Trading Premium (Upgrade) (NASDAQ:ABCL) - Seeking Alpha
Sentiment Watch: What hedge funds are buying AbCellera Biologics IncEarnings Overview Summary & Weekly Stock Breakout Alerts - baoquankhu1.vn
AbCellera Biologics (ABCL) Goldman Sachs 45th Annual Global Healthcare Conference summary - Quartr
AbCellera Biologics Inc. (ABCL) - minichart.com.sg
Aug Intraday: Is AbCellera Biologics Inc affected by consumer sentiment - baoquankhu1.vn
AbCellera Biologics Eyes Integrated Biotech Shift; ABCL635 Phase II Data Due in Q3 at Forum - MarketBeat
Is AbCellera Biologics Inc a potential multi bagger2026 Sector Moves & Smart Money Movement Tracker - baoquankhu1.vn
Bear Alert: Is AbCellera Biologics Inc part of any ETF2026 Key Lessons & AI Optimized Trading Strategy Guides - baoquankhu1.vn
AbCellera at KeyBanc Forum: Strategic Advances in Biotech By Investing.com - Investing.com Canada
New CMO Appointment Strengthens AbCellera Biologics Inc. (ABCL)’s Push Into Immunology and Beyond - MSN
AbCellera Biologics Inc. (NASDAQ:ABCL) Receives Average Rating of "Hold" from Analysts - MarketBeat
AbCellera Biologics Q1 2025 Earnings Preview - MSN
AbCellera Biologics Pivots to Pipeline as ABCL635 Phase II Hot Flash Data Nears, Exec Says - MarketBeat
AbCellera at TD Cowen Conference: Strategic Pipeline Insights By Investing.com - Investing.com Canada
DNB Asset Management AS Buys Shares of 656,208 AbCellera Biologics Inc. $ABCL - MarketBeat
Holdings Thermopylae Increases Stake in AbCellera Biologics Inc - GuruFocus
Thermopylae adds AbCellera (ABCL) shares in open-market buy - Stock Titan
AbCellera (ABCL) Is Up 18.8% After Pivoting To Clinical Stage And Filing Share Offering - simplywall.st
Thermopylae Holdings adds AbCellera (ABCL) shares in $3.27 open-market buy - Stock Titan
AbCellera (ABCL) CFO adds 42,600 shares in open-market stock purchase - Stock Titan
A Look At AbCellera Biologics (ABCL) Valuation After Narrower Losses And Pipeline Progress - simplywall.st
Decoding AbCellera Biologics Inc (ABCL): A Strategic SWOT Insigh - GuruFocus
Why AbCellera (ABCL) Is Up 11.5% After Narrowing Losses And Expanding ESOP Share Capacity – And What's Next - Yahoo Finance
AbCellera Biologics (ABCL) Pivots to Clinical Stage as 2025 Revenue Hits $75M - Insider Monkey
Abcellera Warns Growing Generative AI Use Raises Cybersecurity, Privacy, and Operational Risks - TipRanks
Finanzdaten der Abcellera Biologics Inc-Aktie (ABCL)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.90%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):